Aurobindo Pharma
Growth unavailable
Q2 FY2027 · Period ended 30 Sep 2026
Basis: Consolidated, as stated in the company's Q2 FY2027 press release dated 4 Nov 2026
Reported revenue (₹ crore, except margin): 10,263
Read summary and comparison caveats
Aurobindo Pharma reported September-quarter consolidated revenue from operations of ₹10,263 crore, with printed growth of 23.9% year on year and 12.2% sequentially. EBITDA before forex and other income was ₹2,156 crore. The release labels net profit for the period at ₹1,124 crore, compared with ₹848 crore a year earlier. The release-based EBITDA margin was 21.0%.
- The five-page company press release dated 4 Nov 2026 was read in full on 17 Nov; its headline table was visually checked. This entry uses the rounded consolidated press-release table, not standalone or half-year figures. It is not a substitute for the signed financial statement and review report.
- Amounts are already in INR crore in this release. No unit conversion or percentage calculation is applied. Year ago is Q2 FY2026; previous quarter is Q1 FY2027. All growth percentages and basis-point changes shown above are printed in the source.
- EBITDA is explicitly before forex and other income; PBT is explicitly before share of profit/loss of joint ventures. These labels are retained and are not treated as statutory total PBT or interchangeable profit measures.
- The release calls ₹1,124 crore net profit for the period without a separate non-controlling-interest reconciliation in its headline table. That label is retained, rather than inferring profit attributable to owners or adjusted PAT. The release does not provide an exceptional-item reconciliation; none is invented here.
- The margin table prints 21.0% versus 20.3% and 20.6%, with changes of 75 bps and 45 bps. Printed basis-point changes are retained, not recalculated from rounded displayed margins.
- The release describes growth supported by organic performance and integration of inorganic opportunities. This table is not a like-for-like organic-growth calculation. Forward-looking management comments, cash-flow claims, product approvals and dividend information are not used as earnings measures.
- Selected own-source coverage, not complete market coverage. The restricted investor presentation was not used; this entry is original factual prose from the separately published press release.
Checked 17 Nov 2026
Open original filing